US Stock MarketDetailed Quotes

LUNG Pulmonx

Watchlist

8.260
+0.010+0.12%

Close Sep 26 16:00 ET

323.40MMarket Cap-5506P/E (TTM)

Pulmonx Stock Forum

Jaguar8

Sep 10 04:30

NEWS

$Pulmonx (LUNG.US)$
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
Pulmonx (Nasdaq: LUNG) presented clinical data from two significant studies at the European Respiratory Society Congress 2024. The AeriSeal® CONVERT trial showed that 77.6% of patients with collateral ventilation (CV+) successfully converted to CV- status after treatment with the AeriSeal System...

Hmm

Pulmonx's balance sheet suggests it could easily eliminate its debt. Its revenue growth over the last year indicates potential profitability. However, it had an EBIT loss over the last year, with a negative free cash outflow of US$40m and a US$61m accounting loss.

Is Pulmonx (NASDAQ:LUNG) Using Debt Sensibly?

Moomoo AI

Dec 8, 2023 18:24

Insider sales of Pulmonx shares below the current price, including by Glendon French, could indicate comfort with a lower valuation. A lack of insider purchases in the past year and low insider ownership might suggest a lack of alignment between management and small shareholders.